Form D · Biotechnology
Elion Therapeutics, Inc.
New York, NY · CIK 0002028346
Offering snapshot reported Jun 26, 2024 · SEC filing
- Reported sold
- $25.4M Offering amount: $83.8M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 11, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 26, 2024 | Initial | $25,436,790 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-516941
Source: Form D, filed Jun 26, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jim Flynn | Director |
| Martin Heidecker | Director |
| Jonathan Leff | Director |
| Kieren Marr | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Deerfield Management Company Lp 345 Park Avenue South
New York, NY, 10010
New York, NY, 10010